



The Nifty previous session ended 0.62% down at 16025.80. It opened on a flat note and remained extremely choppy throughout the session towards finishing off with another bearish candle. Short-term chart pattern suggesting range-bound oscillation in the price band of 16000-16400. Next support below 16000 is placed around 15950.

On the Nifty hourly chart, direction of the leading indicators pointing towards range-bound oscillation in the price band of 15950-16400.

Nifty patterns on multiple periods suggesting; retracement towards critical supports may again find buyers. Oversold Index majors likely to play a critical role in taking the Nifty towards 16400 levels.

Nifty Crucial Supports & Resistances-

Supports- 16000, 15950 Resistances- 16400, 16480

Open Positional Calls-

T+10 INST POSITIONAL BUY-

| Cash Segment | AXIS BANK @ 650 -640, TGT- 700, Closing SL- Below 610

T+10 INST POSITIONAL BUY-


| Cash Segment | HDFC BANK @ 1310-1300, TGT- 1400, Closing SL- Below 1250

T+10 INST POSITIONAL BUY-

| Cash Segment | LT @ 1650-1630, TGT- 1720, Closing SL- Below 1600

| Key Contents | Page No. |
|---------------|----------|
| Result Update | 4 |

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks declined for the third day in a row, dragged by losses in information technology, consumer discretionary and realty stocks.

Nifty index ended 0.62% lower at 16,0256 The broader markets represented by the Nifty 500 Index ended 1.16% lower, ending at 13,588. Among the sectorial indices, Nifty Finance was the top gainer, gaining by 0.68%, followed by Nifty Bank gaining by 0.14%. Nifty IT was the top loser, losing by 3.38%.

NTPC was the top gainer, gaining by 3.91%, followed by HDFC Life and SBI Life which gaining by 2.93% & 2.11%. Asian Paints was the top loser, losing by 8.06%, followed by Adani Ports & SE and Divi's Lab which losing by 5.88% & 3.89% respectively.

The Advance : Decline ratio stood at 354:1806

Market Turnover (In Crore) 25-05-2022

| Name | Last | Previous |
|----------|------------|------------|
| NSE Cash | 49461.52 | 51647.55 |
| NSE F&O | 9473001.53 | 8173704.65 |
| BSE Cash | 3,222.87 | 2,986.27 |
| BSE F&O | *NA | 244.09 |

FII Derivatives Flow (In Crore) 24-05-2022*

| Instrument | Purchase | Sale | Net |
|--------------|-----------|-----------|---------|
| Index Future | 4703.69 | 5347.63 | 643.94 |
| Index Option | 674406.60 | 674918.69 | 512.09 |
| Stock Future | 60724.92 | 58946.59 | 1778.33 |
| Stock Option | 8863.32 | 8914.29 | 50.97 |

Institutional Flow (In Crore) 25-05-2022

| Institution | Purchase | Sale | Net |
|-------------|----------|---------|---------|
| FII | 6371.24 | 8174.30 | 1803.06 |
| DII | 7025.71 | 4795.89 | 2229.82 |

*Data not updated till 6:20PM

NIFTY Top Gainers

| Name | %1D | %5D | Day Vol | Avg 5 Day Vol |
|---------------------|------|------|----------|---------------|
| NTPC | 3.91 | 2.79 | 19926619 | 17958230 |
| HDFC Life Insurance | 2.93 | 3.47 | 5339885 | 3182886 |
| SBI Life Insurance | 2.11 | 2.06 | 3185769 | 850893 |
| Bharti Airtel | 1.47 | 1.14 | 4188088 | 7946998 |
| HDFC | 1.39 | 2.42 | 3147555 | 3540632 |

NIFTY Top Losers

| Name | %1D | %5D | Day Vol | Avg 5 Day Vol |
|---------------------|------|-------|---------|---------------|
| Tech Mahindra | 3.48 | 9.55 | 4711542 | 3719733 |
| UPL | 3.60 | 6.95 | 1484158 | 2173249 |
| Divi'S Laboratories | 3.89 | 19.40 | 1567485 | 1657694 |
| Adani Ports & SE | 5.88 | 6.83 | 7699306 | 5668243 |
| Asian Paints | 8.06 | 8.45 | 3381427 | 887142 |

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.asp>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

| Name | Index | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|----------------|----------|----------|------|-------|-------|-------|-------|
| Sensex | 53749.26 | 303.35 | 0.56 | 0.85 | 6.29 | 3.78 | 5.35 |
| Nifty | 16025.80 | 99.35 | 0.62 | 1.32 | 6.83 | 3.80 | 4.73 |
| BSE M Cap | 21829.06 | 430.49 | 1.93 | 3.72 | 9.94 | 5.76 | 1.05 |
| BSE S Cap | 25123.30 | 760.55 | 2.94 | 4.85 | 12.46 | 5.02 | 7.59 |
| Nifty MC 100 | 26918.70 | 676.60 | 2.45 | 4.24 | 10.91 | 3.70 | 5.29 |
| BSE Auto | 25145.99 | 208.91 | 0.82 | 1.25 | 1.27 | 1.54 | 7.36 |
| BSE Capgoods | 25793.51 | 644.91 | 2.44 | 0.94 | 6.35 | 5.11 | 14.99 |
| BSE FMCG | 13865.94 | 56.16 | 0.40 | 0.26 | 0.83 | 7.27 | 6.90 |
| BSE Metal | 17176.52 | 245.85 | 1.41 | 11.39 | 20.67 | 12.84 | 5.83 |
| BSE Oil&Gas | 18310.08 | 279.44 | 1.50 | 3.89 | 8.69 | 8.36 | 13.80 |
| BSE Healthcare | 22054.92 | 339.13 | 1.51 | 3.08 | 9.04 | 5.02 | 10.41 |
| BSE Power | 4231.79 | 31.99 | 0.75 | 3.86 | 13.10 | 11.52 | 51.81 |
| BSE Realty | 3024.54 | 94.08 | 3.02 | 3.68 | 14.73 | 12.21 | 13.18 |
| BSE ConsDur | 36396.52 | 516.14 | 1.40 | 2.87 | 15.70 | 13.82 | 10.05 |
| BSE Bank | 39791.33 | 85.26 | 0.21 | 0.77 | 5.15 | 5.00 | 1.03 |
| BSE IT | 28096.72 | 925.78 | 3.19 | 7.78 | 12.38 | 15.25 | 4.15 |

Bond Markets

| Name | Yield | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|-------------|-------|----------|-------|-------|-------|--------|--------|
| US | 2.73 | 0.03 | 0.91 | 5.50 | 3.34 | 38.94 | 74.85 |
| UK | 1.86 | 0.02 | 1.22 | 0.05 | 1.25 | 27.93 | 137.15 |
| Brazil | 5.70 | 0.05 | 0.89 | 1.91 | 3.00 | 10.69 | 47.79 |
| Japan | 0.21 | 0.02 | 10.13 | 13.06 | 13.77 | 0.95 | 173.08 |
| Australia | 3.24 | 0.08 | 2.35 | 6.36 | 3.51 | 45.10 | 92.17 |
| India | 7.30 | 0.06 | 0.76 | 0.79 | 3.69 | 8.18 | 22.25 |
| Switzerland | 0.69 | 0.00 | 0.29 | 7.84 | 16.49 | 116.20 | 510.65 |
| Germany | 0.92 | 0.05 | 5.17 | 10.97 | 9.56 | 296.97 | 649.10 |

Currency

| Name | Rate | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|-----------|--------|----------|------|------|------|------|-------|
| INR | 77.53 | 0.06 | 0.08 | 0.07 | 1.07 | 2.88 | 6.12 |
| USD Index | 102.30 | 0.45 | 0.44 | 1.45 | 0.54 | 5.89 | 14.13 |
| YUAN | 6.69 | 0.04 | 0.61 | 0.89 | 2.02 | 5.63 | 4.24 |
| GBP | 1.25 | 0.00 | 0.35 | 1.19 | 1.99 | 6.87 | 11.76 |
| EUR | 1.07 | 0.01 | 0.74 | 1.84 | 0.52 | 5.42 | 13.00 |
| YEN | 126.97 | 0.14 | 0.11 | 0.99 | 0.92 | 8.99 | 14.33 |

Freight

| Name | Index | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|--------------|---------|----------|------|------|-------|--------|---------|
| Baltic Dry | 3253.00 | 116.00 | 3.44 | 2.01 | 38.07 | 56.70 | 15.81 |
| Baltic Dirty | 1119.00 | 5.00 | 0.45 | 3.32 | 19.03 | 2.44 | 82.25 |
| SG Dubai HY | 25.04 | 1.22 | 5.12 | 4.97 | 2.20 | 173.96 | 11281.8 |

Global Indices

| Name | Index | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|----------------|----------|----------|------|------|-------|-------|-------|
| Dow Jones | 31928.62 | 48.38 | 0.15 | 2.22 | 6.23 | 6.25 | 6.95 |
| Nasdaq | 11264.45 | 270.82 | 2.35 | 6.01 | 13.38 | 17.75 | 17.52 |
| S&P 500 | 3941.48 | 32.27 | 0.81 | 3.60 | 8.25 | 10.11 | 5.89 |
| FTSE100 | 7496.16 | 12.51 | 0.17 | 0.79 | 1.58 | 0.10 | 6.64 |
| CAC40 | 6230.45 | 21.96 | 0.35 | 1.92 | 3.38 | 7.72 | 2.49 |
| DAX | 13879.89 | 37.12 | 0.27 | 0.89 | 0.30 | 4.70 | 10.23 |
| Mexico IPC | 51304.04 | 72.85 | 0.14 | 0.31 | 2.66 | 2.38 | 5.07 |
| Brazil Bovespa | 110580.8 | 0.00 | 0.00 | 1.65 | 0.09 | 2.26 | 10.09 |
| Russian RTS | 1267.60 | 5.93 | 0.47 | 4.55 | 34.72 | 35.31 | 19.79 |
| Japan Nikkei | 26677.80 | 70.34 | 0.26 | 0.87 | 0.08 | 0.76 | 6.86 |
| Hang Seng | 20171.27 | 59.17 | 0.29 | 2.29 | 1.19 | 11.40 | 30.84 |
| Taiwan Index | 16104.03 | 140.40 | 0.88 | 1.18 | 3.25 | 8.77 | 3.24 |
| Shanghai Comp | 3107.46 | 36.54 | 1.19 | 0.70 | 7.66 | 9.97 | 13.52 |
| KOSPI | 2617.22 | 11.35 | 0.44 | 0.33 | 1.91 | 2.22 | 17.40 |
| Malaysia KLCI | 1535.56 | 4.26 | 0.28 | 1.24 | 3.83 | 3.53 | 2.68 |
| Jakarta Comp | 6883.50 | 30.64 | 0.44 | 1.33 | 4.82 | 0.07 | 18.36 |
| Philippine SE | 6597.76 | 20.31 | 0.31 | 1.93 | 5.48 | 8.52 | 4.05 |
| Thai Exch | 1625.18 | 1.05 | 0.06 | 0.30 | 2.62 | 3.26 | 3.61 |

Indian Indices

| Name | Index | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|-------------|--------|----------|------|------|-------|-------|--------|
| NYMEX Crude | 111.01 | 1.29 | 1.18 | 1.34 | 12.71 | 21.26 | 68.09 |
| BRENT Crude | 114.67 | 1.16 | 1.02 | 5.14 | 12.29 | 27.35 | 77.97 |
| Natural Gas | 8.91 | 0.11 | 1.25 | 6.43 | 30.87 | 96.69 | 240.70 |

LME

| Name | Index | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|------------------|---------|----------|------|------|-------|-------|-------|
| Gold(\$/Ounce) | 1855.44 | 10.52 | 0.56 | 2.17 | 2.21 | 1.77 | 2.28 |
| Silver(\$/Ounce) | 21.80 | 0.30 | 1.36 | 1.83 | 7.65 | 10.13 | 22.08 |
| Aluminium | 2874.90 | 58.35 | 1.99 | 0.35 | 11.13 | 16.31 | 22.05 |
| Copper | 9459.00 | 129.50 | 1.35 | 0.78 | 6.47 | 4.63 | 4.73 |
| Zinc | 3798.75 | 1.75 | 0.05 | 3.64 | 15.55 | 3.76 | 29.40 |
| Lead | 2161.05 | 35.95 | 1.64 | 3.62 | 9.54 | 7.83 | 1.68 |

Agro Commodities

| Name | Price | Net Chng | %1D | %5D | %1M | %3M | %1Y |
|---------|---------|----------|------|------|------|-------|-------|
| Coffee | 214.45 | 0.80 | 0.37 | 1.45 | 2.83 | 9.59 | 34.66 |
| Cotton | 123.00 | 0.78 | 0.63 | 4.78 | 3.99 | 22.60 | 60.85 |
| Sugar | 19.66 | 0.09 | 0.46 | 0.86 | 4.13 | 12.47 | 24.75 |
| Wheat | 1121.50 | 33.25 | 2.88 | 8.88 | 4.57 | 31.94 | 72.21 |
| Soybean | 1677.50 | 15.50 | 0.92 | 0.89 | 0.13 | 6.63 | 26.51 |

Deepak Fertilizers & Petrochemicals Corp

Net profit of Deepak Fertilizers & Petrochemicals Corp rose 146.89% to Rs 279.70 crore in the quarter ended March 2022 as against Rs 113.29 crore during the previous quarter ended March 2021. Sales rose 27.77% to Rs 2012.48 crore in the quarter ended March 2022 as against Rs 1575.08 crore during the previous quarter ended March 2021. For the full year, net profit rose 69.44% to Rs 678.27 crore in the year ended March 2022 as against Rs 400.31 crore during the previous year ended March 2021. Sales rose 31.93% to Rs 7663.29 crore in the year ended March 2022 as against Rs 5808.49 crore during the previous year ended March 2021.

Adani Ports & SE

Adani Ports and Special Economic Zone Limited has reported a 21.78 per cent decline in consolidated net profit to Rs 1,033 crore for the fourth quarter ended March 2022. The country's largest integrated logistics player had clocked a consolidated net profit of Rs 1,321 crore in the corresponding period of the previous fiscal. Consolidated total income of the company increased to Rs 4,417.87 crore for the fourth quarter of the last fiscal as against Rs 4,072.42 crore in the year-ago period. Total expenses also rose to Rs 3,309.18 crore in the latest quarter under review as against Rs 2,526.91 crore in the same period a year ago.

Zee Media Corporation

Net loss of Zee Media Corporation reported to Rs 51.45 crore in the quarter ended March 2022 as against net profit of Rs 10.50 crore during the previous quarter ended March 2021. Sales rose 35.42% to Rs 247.73 crore in the quarter ended March 2022 as against Rs 182.93 crore during the previous quarter ended March 2021. For the full year, net loss reported to Rs 117.72 crore in the year ended March 2022 as against net profit of Rs 75.74 crore during the previous year ended March 2021. Sales rose 33.55% to Rs 866.86 crore in the year ended March 2022 as against Rs 649.07 crore during the previous year ended March 2021.

Strides Pharma

The drug maker reported a 36.6% decline in consolidated net profit to Rs 29.22 crore on a 4.7% fall in net revenue from operations to Rs 866.02 crore in Q4 FY22 over Q4 FY21. The company recorded a pre-tax loss of Rs 102.52 crore in Q4 FY22 as against a pre-tax profit of Rs 55.23 crore in Q4 FY21. Total expenses surged 22.2% to Rs 944.44 crore in the last quarter from Rs 772.84 crore reported in the same period last year. EBITDA slumped 71% year on year to Rs 46.1 crore in the quarter ended 31 March 2022. Meanwhile on the margins front, EBITDA margin tumbled to 5.3% in Q4 FY22 from 17.6% posted in Q4 FY21 while gross margin slipped to 50.9% in Q4 FY22 from 59.2% registered in the corresponding quarter last year. On full year basis, the pharma company reported a consolidated net loss of Rs 460.21 crore in financial year ended 2022 as against a net profit of Rs 268.44 crore in financial year ended 2021. Revenue from operations declined 7.4% year on year to Rs 3,070.25 crore in FY22 over FY21.

rites

RITES reported a marginally lower consolidated net profit of Rs 136.75 crore in Q4 FY22 from Rs 137.73 crore posted in Q4 FY21. Net sales surged 21.7% to Rs 766.02 crore for the quarter ended 31 March 2022 from Rs 629.36 crore recorded in the corresponding period last year. Profit before tax advanced 9.1% to Rs 200.67 crore in Q4 FY22 from Rs 183.90 crore in Q4 FY21. Total expenditure spiked 24.5% to Rs 561.55 crore in Q4 FY22 over Q4 FY21.

Dalmia Bharat Sugar & Industries

Net profit of Dalmia Bharat Sugar & Industries rose 8.98% to Rs 55.58 crore in the quarter ended March 2022 as against Rs 51.00 crore during the previous quarter ended March 2021. Sales rose 75.20% to Rs 856.00 crore in the quarter ended March 2022 as against Rs 488.59 crore during the previous quarter ended March 2021. For the full year, net profit rose 8.96% to Rs 293.64 crore in the year ended March 2022 as against Rs 269.50 crore during the previous year ended March 2021. Sales rose 12.39% to Rs 3018.25 crore in the year ended March 2022 as against Rs 2685.57 crore during the previous year ended March 2021.

eClerx Services

Net profit of eClerx Services rose 20.26% to Rs 118.76 crore in the quarter ended March 2022 as against Rs 98.75 crore during the previous quarter ended March 2021. Sales rose 25.14% to Rs 591.67 crore in the quarter ended March 2022 as against Rs 472.82 crore during the previous quarter ended March 2021. For the full year, net profit rose 47.72% to Rs 417.40 crore in the year ended March 2022 as against Rs 282.56 crore during the previous year ended March 2021. Sales rose 38.09% to Rs 2160.35 crore in the year ended March 2022 as against Rs 1564.49 crore during the previous year ended March 2021.

Aster DM Health

Aster DM Health reported standalone quarterly numbers Net Sales at Rs 290.79 crore in March 2022 up 24.04% from Rs. 234.43 crore in March 2021. Quarterly Net Profit at Rs. 62.87 crore in March 2022 up 541.5% from Rs. 14.24 crore in March 2021. EBITDA stands at Rs. 98.54 crore in March 2022 up 466% from Rs. 17.41 crore in March 2021. Aster DM Health EPS has increased to Rs. 1.26 in March 2022 from Rs. 0.29 in March 2021.

Metropolis Healthcare

Metropolis Healthcare declined 1.37% to Rs 1,665.45 after the diagnostic company posted a 34.8% decline in consolidated net profit of Rs 39.99 crore in Q4 FY22 from Rs 61.35 crore posted in Q4 FY21. Net sales grew 4.9% to Rs 305.90 crore in quarter ended 31 March 2022 from Rs 291.73 crore reported in the corresponding quarter previous year. The company reported an 18.3% rise in total expenditure to Rs 231.05 crore in Q4 FY22 over Q4 FY21. Profit before tax tumbled 30.8% to Rs 56.47 crore in Q4 FY22 from Rs 81.65 crore recorded Q4 FY21. Reported EBITDA in Q4 FY22 stood at Rs 79.4 crore, down 18% from Rs 96.8 crore in Q4 FY21. Reported EBITDA Margin declined to 26% in Q4 FY22 from 33.2% in Q4 FY21.

Coal India

Coal India Ltd reported 46% jump in consolidated net profit at Rs 6,693 crore for the quarter ending March 31, 2022. It reported consolidated net profit of Rs 4,587 crore in the year-ago period. The company's consolidated revenue from operations rose 22% to Rs 32,707 crore as against Rs 26,700 crore in the year-ago period. The company's Board of Directors had recommended payment of final dividend of Rs 3 per share for FY22.

NHPC

Net profit of NHPC rose 34.67% to Rs 560.09 crore in the quarter ended March 2022 as against Rs 415.90 crore during the previous quarter ended March 2021. Sales rose 12.25% to Rs 1505.76 crore in the quarter ended March 2022 as against Rs 1341.48 crore during the previous quarter ended March 2021. For the full year, net profit rose 9.02% to Rs 3537.71 crore in the year ended March 2022 as against Rs 3245.06 crore during the previous year ended March 2021. Sales declined 1.80% to Rs 8353.80 crore in the year ended March 2022 as against Rs 8506.58 crore during the previous year ended March 2021.

Max Healthcare

Max Healthcare Institute reported on its profit after tax increased by 58 per cent to Rs 172 crore for the fourth quarter ended March 2022. The company had reported a net profit of Rs 109 crore for the January-March quarter of 2020-21 fiscal. Gross revenue rose to Rs 1,298 crore for the period under review as compared with Rs 1,161 crore in the year-ago period. For the year ended March 31, 2022, the healthcare provider posted a net profit of Rs 837 crore. It had reported a net loss of Rs 95 crore in FY21 fiscal.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

| Company | Details |
|------------------------------|--|
| Sawaca Business Machines Ltd | 10 for 1 stock split effective 26-05-22 |
| Visaka Industries Ltd | Cash dividend of INR8 effective 26-05-22 |
| ITC Ltd | Cash dividend of INR6.25 effective 26-05-22 |
| Sawaca Business Machines Ltd | Stock dividend of INR1.10 effective 26-05-22 |
| Vinny Overseas Ltd | Stock dividend of INR1.10 effective 26-05-22 |
| Capacit'e Infraprojects Ltd | Corporate meeting effective 26-05-22 |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Domestic Events

- No events

Global Events

- The U.S. GDP growth rate for Q1 2022.
- The U.S. Pending Home Sales for April 2022.
- The U.S. Initial Jobless Claims May 21, 2022.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Jaydeb Dey and Shreyansh N. Mehta Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
